04
Jul

Invictus Receives $5.8 Million from Warrant and Option Exercises and Issues Incentive Stock Options

Vancouver, BC, July 4, 2018 - INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTC: IVITF; FRA: 8IS1) is pleased to announce that for the current fiscal year, which commenced on February 1, 2018, the Company has received $5,777,267 from the exercise of previously issued warrants and options. A total of 4,346,731 warrants and 337,500 options were exercised for proceeds of $5,267,467 and $509,800, respectively. As a result of such exercises, the Company currently has a total of 96,623,857 common shares issued and outstanding.

Invictus expects to use these proceeds to help fund its ongoing construction program and overall operations. The Company anticipates a total cannabis cultivation footprint of 262,000 square feet by the end of 2018 and 846,000 square feet by end of 2019. Invictus has approximately 9.9 million warrants and 9.4 million options outstanding that, if exercised, would bring in an additional $19.7 million and $14.9 million in cash funds to the Company.

Invictus has also granted 120,000 incentive stock options to certain eligible persons of the Company. Each stock option has an exercise price of $1.50 and is exercisable into one common share of the Company. The options vest 1/3 in 3 months, 1/3 in nine months, and 1/3 in fifteen months and are exercisable over a period of five years. The stock options were granted subject to the terms and conditions of the Company’s Stock Option Plan.

About Invictus

Invictus owns and operates two cannabis production facilities, both with sales licenses, under the ACMPR in Canada, with the vision of producing a variety of high quality and low-cost cannabis products to the global market, as regulations permit. The Company’s wholly owned subsidiary, Acreage Pharms Ltd. (“Acreage Pharms”), is located in West-Central Alberta. The Company’s 50% owned AB Laboratories Inc. (“AB Labs”), is located in Hamilton, Ontario. AB Ventures Inc. (“AB Ventures”) owns 100 acres of land near Hamilton, Ontario, to be used for future cannabis cultivation. Recently, the Company announced that it has entered into a binding letter of intent for an option to acquire an applicant (the “OptionCo”) under the ACMPR. Combined, the Company expects to have approximately 262,000 and 846,000 square feet of cannabis production capacity by the end of 2018 and 2019, respectively.

Gene Simmons, music legend and media mogul, conveys the vision of Invictus as the Chief Evangelist Officer.

The Company’s wholly owned subsidiary, Poda Technologies Ltd. (“Poda”), has developed the world’s first zero-cleaning vaporizer system. Poda’s fully biodegradable pods are self-contained, and do not contaminate the vaporizer with odor, flavor or residue.

Finally, the Company’s 82.5% owned Future Harvest Development Ltd. (“Future Harvest”) is a high-quality Fertilizer and Nutrients manufacturer, based in Kelowna, British Columbia. Future Harvest has been in operation for over 20 years under the brand Plant Life Products and Holland Secret.

Invictus’ Canadian Production Footprint:

News table

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Chairman and CEO

Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(604) 537-8676

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including the expected use of the proceeds from the Company’s option and warrant exercises and the potential production capacity of OptionCo, AB Labs, AB Ventures and Acreage Pharms, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that there will be no material change in the Company’s business or market conditions that will require the Company to alter its current anticipated use of the proceeds from the option and warrant exercises that OptionCo, AB Labs, AB Ventures and Acreage Pharms will be successful in reaching their potential production capacity, OptionCo, AB Labs, AB Ventures and Acreage Pharms’ production facilities will be completed as anticipated, regulatory approval will be granted as anticipated, OptionCo, AB Labs, AB Ventures and Acreage Pharms will reach full production capacity on the timeline anticipated by the Company,.  These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, there will be a material change in the Company’s business or market conditions that will require the Company to alter its current anticipated use of the proceeds from the option and warrant exercises OptionCo, AB Labs, AB Ventures and Acreage Pharms will not be successful in reaching its potential production capacity, OptionCo, AB Labs, AB Ventures and Acreage Pharms production facilities will not be completed as anticipated, construction delays, regulatory approval will not be granted as anticipated and therefore, the anticipated timing of OptionCo, AB Labs, AB Ventures and Acreage Pharms reaching full production capacity will be delayed.  Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Recent Posts

INVICTUS’ ACREAGE PHARMS COMPLETES SHIPMENT OF RECREATIONAL CANNABIS TO BRITISH COLUMBIA

September 25, 2018

Invictus provides update on German partnership and EU-GMP certification

September 24, 2018

Invictus Hires Ex-Heineken Executive Kevin Smith As VP Recreational Sales; Sarah Hardy As VP Medical Sales

September 17, 2018

Invictus Acreage Pharms To Become A Registered Cannabis Supplier In Saskatchewan

September 11, 2018
 

Categories

Archives

 September 2018
 August 2018
 July 2018
 June 2018
 May 2018
 April 2018
 March 2018
 February 2018
 January 2018
 December 2017
 November 2017
 October 2017
 September 2017
 August 2017
 July 2017
 June 2017
 May 2017
 April 2017
 March 2017
 February 2017
 January 2017
 December 2016
 November 2016
 October 2016
 August 2016
 March 2016
 February 2016
 December 2015
 November 2015
 October 2015
 September 2015

Download our Investor Deck





Download our Investor Deck